These sources consist of legitimate science or are evidence based through the use of credible scientific sourcing. Legitimate science follows the scientific method, is unbiased and does not use emotional words. These sources also respect the consensus of experts in the given scientific field and strive to publish peer reviewed science. Some sources in this category may have a slight political bias, but adhere to scientific principles. See all Pro-Science sources.
Factual Reporting: MIXED
Notes: Frontiers Media is an academic publisher of peer-reviewed open access scientific journals currently active in science, technology, and medicine. It was founded in 2007 by a group of neuroscientists, including Henry and Kamila Markram, and later expanded to other academic fields. Frontiers is based in Lausanne, Switzerland. They publish 59 journals as of 2017.
In review, Frontiers publishes scientific research studies in a wide range of journals. For the most part all of these are sound science with legitimate peer review. However, in 2015 Frontiers Media was added to Beall’s list of Predatory Open Access Journals. In short, Predatory Open Access publishing is an exploitative open-access publishing business model that involves charging publication fees to authors without providing the editorial and publishing services associated with legitimate journals (open access or not). Frontiers has also retracted some studies that were found to be of poor methodology and not thoroughly peer reviewed. Overall, we still rate Frontiers pro-science, but barely. Of the thousands of journal articles they have published only a select few were retracted and the act of retraction shows diligence toward credible science. (D. Van Zandt 3/16/2018)
Latest from Frontiers
The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer
Advancing Regulatory Science With Computational Modeling for Medical Devices at the FDA's Office of Science and Engineering Laboratories
Regulatory Pathway for Licensing Biotherapeutics in Mexico
Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction
Neuraxial Anesthesia in the Geriatric Patient